We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document contains a synopsis of causation occurring in Inflammatory Bowel Disease.
Projects granted during 2014 that have a primary purpose of basic research into the gastrointestinal system, including liver.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Projects granted during 2015 that have a primary purpose of basic research: gastrointestinal system including liver.
The characteristics, diagnosis, management and epidemiology of gastrointestinal infections.
Volume 30 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Volume 26 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Volume 44 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Form L5 for identification of Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Escherichia coli, helicobacter, listeria and yersinia.
Projects granted during 2015 that have a primary purpose of basic research: immune system.
Gastrointestinal diseases can be notified using this form.
Guidance to help professionals in public health and environmental health departments to minimise the risk of transmission of gastrointestinal infections.
Precautions to stop infection spread aimed at public health and environmental health professionals.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Projects granted during 2015 that have a primary purpose of translational and applied research: gastrointestinal disorders.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.